- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
DeepIntent Reveals New Operating System for Pharmaceutical Advertising
DeepIntent OS expected to give publishers access to company’s comprehensive suite.
Image Credit: Adobe Stock Images/VICHIZH
DeepIntent, a healthcare advertising technology organization, has announced the launch of the DeepIntent Operating System, designed to provide CTV platforms access to its audience, measurement, and optimization solutions designed to improve pharmaceutical advertising performance.
"For platforms and publishers to unlock the full potential of their inventory, they need flexibility, transparency, control, and outcomes-driven optimization. We've launched DeepIntent OS to give them those tools to help them thrive in the complex pharma landscape. As DeepIntent continues to drive innovation, we remain committed to harnessing technology to connect patients and providers with the right information to drive better health outcomes," said Chris Paquette, founder, CEO, DeepIntent.
Reference:
1. DeepIntent Unveils Operating System to Power Pharmaceutical Advertising for CTV Publishers and Platforms. PR Newswire. June 5, 2023. Accessed June 5, 2023. https://www.prnewswire.com/news-releases/deepintent-unveils-operating-system-to-power-pharmaceutical-advertising-for-ctv-publishers-and-platforms-301841362.html
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
